SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES

SBIR 主题 081：针对传染性或免疫介导疾病的疫苗的佐剂开发

• 批准号: 10281998
• 负责人: WENDA GAO
• 金额: $ 60万
• 依托单位: ANTAGEN PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10281998
• 关键词: Adjuvant; Antigens; Cell Line; Chimeric Proteins; Cholera Toxin Protomer B; Complement; Complement 3d; Contracts; Development; Disease; Goals; Green Algae; Helicobacter Infections; Helicobacter pylori; Human Resources; Immune; Israel; Link; Mediating; Medical center; Mucosal Immune Responses; National Institute of Allergy and Infectious Disease; Oral; Program Development; Proteins; Route; Small Business Innovation Research Grant; Support Contracts; Vaccine Adjuvant; Vaccines; design; novel vaccines; oral vaccine; preclinical development; protective efficacy; vaccine development; vaccine efficacy

This contract is part of the NIAID Adjuvant Development program, which supports the preclinical development of novel vaccine adjuvant candidates. The goal of this contract is to support the further development of the C3d-CTB adjuvant within the context of a vaccine to protect against H. pylori.

该合同是NIAID佐剂开发计划的一部分，该计划支持新型疫苗佐剂候选物的临床前开发。 该合同的目标是支持C3 d-CTB佐剂在疫苗背景下的进一步开发，以保护免受H。幽门。